Sector News

Trump to pharma: You're 'getting away with murder'

January 12, 2017
Life sciences

At his first press conference since July, Trump said Wednesday that the industry is “getting away with murder” and that the government must require more competitive “bidding” in order to get drug costs down.

Remember the Trump euphoria that hit biopharma stocks after the president-elect captured the Electoral College in November? Well, scratch that.

At his first press conference since July, Trump said Wednesday that the industry is “getting away with murder”—and the government needs to take action.

Trump said the government should require competitive bidding to get drug costs down, claiming that the U.S. can save “billions of dollars” with such a process. He called out pharma lobbyists and their power in Washington. And, repeating a familiar refrain, the president-elect said pharma needs to be pressured to beef up manufacturing in the U.S.

Cue the stock slump: The NASDAQ Biotechnology Index was down 3.67% early Wednesday afternoon as the press conference news broke.

After opening the conference by talking up several recent manufacturing commitments to the U.S., Trump told reporters that the country has to “get our drug industry back. They don’t make them here for a large extent.”

The U.S. can save billions in healthcare costs by subjecting pharma to a competitive bidding process, he said, going on to blast the industry’s lobbying power in Congress. “We’re the largest buyer of drugs in the world and yet we don’t bid properly,” he said.

“They are getting away with murder,” President-elect Trump said. “Pharma has a lot of lobbies, lobbyists and a lot of power. There is very little bidding on drugs.”

“We’re going to start bidding and we are going to save billions of dollars over a period of time.”

Trade group PhRMA’s CEO Steven Ubl said in a statement that his organization is “committed to working” with Trump and Congress “to improve American competitiveness and protect American jobs.” He said biopharma invests $70 billion each year in the U.S. in R&D, an amount higher than any other industry.

Echoing that sentiment, BIO says it is “eager to discuss ways in which all parties can work together to ensure patients have access to the medicines they need, that we do not limit treatment options available for patients and that America remains the global leader in the development of innovative new treatments and cures.”

Trump’s swift pivot to pharma came as a surprise to some amid a conference that was primarily centered around intelligence reports, the media and the president-elect’s plans for his own business as he assumes the presidency.

Wednesday’s remarks are the latest in a series of drug-related statements by Trump that have kept pharma guessing. They follow more than a year of intense scrutiny and countless headlines about drugmakers’ frequent, sometimes extreme, price hikes.

At first, after Trump defeated Democratic presidential nominee Hillary Clinton, a frequent pharma critic, shares in the sector soared. But many industry leaders believed the pricing issue—and related calls for government action—wouldn’t be going away. Allergan CEO Brent Saunders, for one, suggested that peers prepare by policing themselves on drug prices.

And Trump hasn’t shied away from shaming business. He’s slammed corporations several times on Twitter, triggering share declines and bad publicity for those on the receiving end. Among the companies he’s pressed are Boeing and Lockheed Martin, and Saunders has predicted he could hop on the next pharma controversy.

But if the incoming president is willing to get down to business on drug prices, Sen. Amy Klobuchar, who jumped into Mylan’s EpiPen pricing scandal early on by calling for an investigation, said she’s ready to work together. She offered several tactics in a recent USA Today editorial that she contends would help bring prices down.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.